When: MACD bullish cross OR 50 SMA reclaim at $398 on volume ≥4M

Then: Deploy final 34% position

HOLD existing positions with reduced overweight (50-100 bps), no new buys until technical confirmation; tighten stop to below $375

• Stock below 50 SMA, 10 EMA, and 200 SMA at $356 with negative expanding MACD histogram - confirmed short-term downtrend
• 200 SMA at $356 is critical long-term support; 10% gap down occurred ten days ago on news
• Volume of 8.4 million shares on recovery bounce is ambiguous - could be panic selling into strength rather than institutional accumulation
• VWMA still declining and hasn't turned up yet - no confirmed accumulation signal
• P/B conceded as poor metric, but PEG of 2.27 is elevated, especially with binary pipeline risk
• 52% forward EPS growth is consensus estimate, not guaranteed - depends on olpasiran, MariTide, and biosimilar execution
• Pelacarsen failure on September 4 hit AMGN due to olpasiran exposure; OCEAN(a) readout still ahead represents 20-30% downside risk to $270-$300 range if olpasiran fails
• AMGN debt load of $54.6 billion with Net Debt/EBITDA at 2.7x faces structural drag at 5% 10-year rates
• Defensive rotation may reverse if Fed pivots dovish on recession, hitting AMGN twice
• 150-200 bps overweight position too large given unresolved technical and fundamental risks
• Proposed stop at $356 is only 5% below entry but ATR at $10 makes it susceptible to noise; 1.5x ATR stop at $15/$370 would be more appropriate
• Conservative recommendation: 50-100 bps overweight maximum, stop below recent low at $375

→ vs aggressive: Buying into broken momentum without waiting for repair risks catching falling knives; waiting for confirmation is capital preservation, not paralysis

→ vs neutral: The 8.4 million share volume represents ambiguous signature that could be panic selling into strength rather than institutional accumulation; VWMA still declining and hasn't turned up yet

→ vs neutral: The argument that 14% drop means downside is largely priced in is naive - OCEAN(a) readout for olpasiran could cause another 20-30% decline to $270-$300 if trial fails

→ vs neutral: Waiting for 50 SMA reclaim or 200 SMA retest is not excessive caution but appropriate given confirmed downtrend and binary catalyst risk

→ vs aggressive: Consensus 52% forward EPS growth treats estimates as fact; these get revised down after binary events like pelacarsen failure

→ vs neutral: High rates for longer creates structural drag on $54.6B debt load at 2.7x Net Debt/EBITDA; defensive rotation may reverse on dovish Fed pivot causing double hit

→ vs aggressive: 150-200 bps overweight is too large a bet with unresolved technical damage and binary catalyst; position should be halved to 50-100 bps with wider stop at $375

MODERATED BUY with 75-125 basis points overweight, scaled in thirds: 33% initial at current levels, 33% on successful retest/hold of 370-375, 34% after MACD crosses bullish or stock reclaims 50 SMA on volume; stop at 360-365; defined review at Q3 earnings late October and any olpasiran OCEAN(a) cadence update

• Forward earnings multiple: 15.8x for EPS growing 52%
• Dividend yield: 2.65% backed by 8 billion in annual free cash flow
• Q2 revenue: 10 billion representing business acceleration
• EPS year-over-year: up 65%
• Cash on hand: 14 billion
• ATR: 10 dollars (expanded from 8.5 baseline); expect 15-20 dollar weekly ranges
• 200 SMA: 356
• Conservative analyst's 375 stop is too tight relative to ATR; would get stopped on routine intraday swing
• Aggressive analyst's 150-200 bps position is mislabeled prudence; actual concentration risk given binary olpasiran catalyst
• Olpasiran Phase 3 OCEAN(a) readout is genuinely binary; failure could drop stock to 270-300, not just 360
• Aggressive analyst's Tesla 2019 analogy obscures more than reveals given AMGN's concentrated binary asset pipeline
• Moderate position size captures ~70% of upside while capping single-name risk
• MACD still declining; short-term technical trend still broken
• Defined holding period warranted given defensive rotation tailwind near-term but structural valuation headwinds if rates stay elevated through 2027

→ vs aggressive: Volume analysis is too cute; 8.4 million shares recovery is ambiguous between institutional accumulation, short covering, and systematic rebalancing; VWAP still declining contradicts clean accumulation thesis

→ vs aggressive: Claim that downside is largely priced in after 14% drop ignores that olpasiran has its own Phase 3 OCEAN(a) binary readout; failure could drop stock to 270-300, not just 360

→ vs aggressive: Tesla 2019 analogy obscures; Tesla had multiple shots on goal across energy storage, FSD, and automotive with demonstrated commercial progress; AMGN pipeline is more concentrated in binary assets

→ vs conservative: Tightening stop to 375 is worse than trader's original 356; ATR is 10 dollars meaning stock routinely moves 15-20 dollars weekly; 375 stop is only 10 dollars below current price within normal daily noise; guaranteed whipsaw on routine intraday swing

→ vs conservative: Sitting in cash until 50 SMA reclaim or 200 SMA retest treats this as all-or-nothing when it's a sliding scale; 10 billion quarterly revenue, 65% EPS growth, 14 billion cash is not a name to be completely out of; opportunity cost compounds